TEL AVIV, Israel, Sept. 3, 2013 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), today announced that the Company will be presenting at the Stifel Nicolaus 2013 Annual Healthcare Conference. The conference is being held at the Four Seasons Hotel in Boston, Massachusetts.
Yaron Daniely, Chief Executive Officer of Alcobra, is scheduled to present at 3:15 p.m. ET on Wednesday, September 11th. The conference presentation will be broadcast over the Internet as a "live" listen only Webcast. To listen, please go to: http://www.alcobra-pharma.com/events.cfm. An archive of the event will also be available for those unable to listen live.
Investors attending the conference interested in meeting with management should contact their Stifel Nicolaus representative.
About Alcobra Ltd.
Alcobra Ltd. is an emerging biopharmaceutical company primarily focused on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD). MG01CI has completed Phase II studies to treat Attention Deficit Hyperactivity Disorder. The company was founded in 2008 and is headquartered in Tel Aviv, Israel.
CONTACT: U.S. Investor Contacts: KCSA Strategic Communications Jeffrey Goldberger / Garth Russell +1 212.896.1249 / +1 212.896.1250 email@example.com / firstname.lastname@example.org Israel Investor Contact: Investor Relations Ltd. Moran Meir-Beres +011972-3-5167620 email@example.comSource:Alcobra Ltd.